Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1068
- Registration Number
- NCT04478266
- Locations
- 🇺🇸
Investigational Site Number :8400029, Santa Monica, California, United States
🇺🇸Investigational Site Number :8400038, Fullerton, California, United States
🇺🇸Investigational Site Number :8400013, Westwood, Kansas, United States
A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 68
- Registration Number
- NCT04469621
- Locations
- 🇦🇷
Investigational Site Number 0320001, Caba, Argentina
🇨🇱Investigational Site Number 1520003, Santiago, Chile
🇷🇺Investigational Site Number 6430002, Moscow, Russian Federation
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 586
- Registration Number
- NCT04458831
- Locations
- 🇺🇸
University of Arkansas Medical Sciences Site Number : 8400021, Little Rock, Arkansas, United States
🇺🇸St. Joseph Heritage Healthcare Site Number : 8400008, Fullerton, California, United States
🇺🇸University of California San Francisco (PARENT) Site Number : 8400009, San Francisco, California, United States
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 700
- Registration Number
- NCT04458051
- Locations
- 🇫🇷
Investigational Site Number : 2500011, Bron, France
🇬🇷Investigational Site Number : 3000006, Athens, Greece
🇬🇷Investigational Site Number : 3000002, Athens, Greece
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 935
- Registration Number
- NCT04456673
- Locations
- 🇺🇸
Radiance Clinical Research Site Number : 8400029, Lampasas, Texas, United States
🇺🇸Cullman Research Center, LLC Site Number : 8400095, Cullman, Alabama, United States
🇺🇸Pulmonary & Sleep Associates of Jasper PC Site Number : 8400090, Jasper, Alabama, United States
Dupilumab Skin Barrier Function Study in Atopic Dermatitis
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 52
- Registration Number
- NCT04447417
- Locations
- 🇺🇸
Investigational Site Number 8400001, Denver, Colorado, United States
🇨🇦Investigational Site Number 1240001, Montreal, Canada
A National Study in Patients With Unexplained Splenomegaly
- Conditions
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 506
- Registration Number
- NCT04430881
- Locations
- 🇫🇷
Investigational site France, France, France
Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 65
- Registration Number
- NCT04418661
- Locations
- 🇺🇸
~University of Texas - MD Anderson Cancer Center Site Number : 8400001, Houston, Texas, United States
🇨🇱Investigational Site Number : 1520002, Temuco, Chile
🇨🇳Investigational Site Number : 1580001, Taipei, Taiwan
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)
- Conditions
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1131
- Registration Number
- NCT04411641
- Locations
- 🇺🇸
University of Alabama MS Center-Site Number:8400013, Birmingham, Alabama, United States
🇺🇸Center for Neurology and Spine-Site Number:8400089, Phoenix, Arizona, United States
🇺🇸Arcadia Neurology Center-Site Number:8400070, Arcadia, California, United States
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 900
- Registration Number
- NCT04410991
- Locations
- 🇺🇸
CHI Saint Joseph Medical Group Neurology-Site Number:8400110, Lexington, Kentucky, United States
🇮🇳Investigational Site Number :3560005, Chandigarh, India
🇷🇺Investigational Site Number :6430007, Moscow, Russian Federation